Elamipretide Uses: What the Research Shows

Elamipretide is a mitochondria-targeted tetrapeptide studied for a small group of serious conditions, most notably Barth syndrome, primary mitochondrial myopathy, heart failure, and certain eye diseases. It works by binding to cardiolipin on the inner mitochondrial membrane, which helps stabilize the cell's energy-producing machinery. Elamipretide is a prescription drug candidate, not a dietary supplement, and it is not approved for general anti-aging or athletic performance use in the United States.

What Is Elamipretide and How Does It Work?

Elamipretide (also known by the research codes SS-31 and MTP-131, and the brand name Forzinity) is a short synthetic peptide made of four amino acids. Its alternating aromatic and basic residues give it a positive charge, which draws it toward the negatively charged inner mitochondrial membrane.

Once inside, elamipretide binds cardiolipin, a phospholipid that is essential for the structure of the electron transport chain. When mitochondria are stressed, cardiolipin oxidizes and the cristae fold structure collapses. Elamipretide appears to shield cardiolipin from that oxidation, supporting ATP production and reducing reactive oxygen species.

That single mechanism explains why the research spans so many organ systems: nearly every cell type depends on mitochondrial energy output.

The Main Elamipretide Uses Being Studied

The development program is not limited to one disease. It covers genetic mitochondrial disorders, cardiac injury, and degenerative eye conditions.

Barth Syndrome

Barth syndrome is a rare X-linked disorder caused by mutations in the TAZ gene. It causes cardiomyopathy, skeletal muscle weakness, growth delay, and low neutrophil counts. Elamipretide is the most advanced therapy in development for this condition and has been tested in the TAZPOWER trial and its open-label extension.

Published results reported improvements in some functional measures, but regulators have questioned how strong that evidence is. Barth syndrome remains the indication closest to a regulatory decision.

Primary Mitochondrial Myopathy

Primary mitochondrial myopathy describes genetic disorders that impair muscle energy metabolism, leading to exercise intolerance and fatigue. The phase 3 MMPOWER-3 trial did not meet its primary endpoint, though secondary and long-term extension analyses suggested possible benefit in some patients.

Heart Failure and Cardiac Ischemia

In the EMBRACE STEMI and EMBRACE-HF trials, elamipretide was given intravenously around episodes of cardiac stress. The goal was to limit reperfusion injury, the damage that occurs when blood flow returns to oxygen-starved heart muscle. Results have been mixed, and no cardiac indication is approved.

Eye Diseases

Subcutaneous elamipretide was studied in dry age-related macular degeneration in the ReCLAIM program, while a topical eye-drop version has been tested in Fuchs endothelial corneal dystrophy and Leber hereditary optic neuropathy. Vision endpoints have shown signals of activity, but these uses remain experimental.

Elamipretide Dosage and Routes Used in Research

Dosing depends entirely on the condition and the trial protocol. The figures below reflect what was published in human studies, not treatment recommendations.

Condition	Route	Dose studied	Stage
Barth syndrome	Subcutaneous injection	40 mg once daily	Most advanced program
Primary mitochondrial myopathy	Subcutaneous injection	40 mg once daily	Phase 3 completed
Reperfusion injury after heart attack	Intravenous infusion	0.05 mg/kg per hour	Phase 2
Heart failure	Intravenous infusion	0.05 mg/kg per hour for 4 hours	Phase 2
Dry age-related macular degeneration	Subcutaneous injection	40 mg once daily	Phase 2
Corneal and optic nerve disease	Topical eye drops	Formulation-specific	Early stage

Reported side effects in trials have included injection-site reactions, headache, and mild gastrointestinal symptoms. Anyone considering elamipretide outside a trial should talk with a physician instead of self-dosing.

Is Elamipretide FDA Approved?

Elamipretide has been developed as a prescription drug under the brand name Forzinity and has been through repeated FDA review for Barth syndrome. That regulatory status has shifted over time, so the FDA's own records are the only reliable source for the current answer.

What is not in dispute is that elamipretide is not approved as a dietary supplement, a cosmetic ingredient, or an over-the-counter wellness product. It is also not approved for anti-aging, weight loss, or athletic performance.

Elamipretide is a mitochondria-targeted peptide that is not sold legally as a consumer supplement in the United States.

How Elamipretide Compares With Other Research Peptides

Many people find elamipretide while browsing the wider peptide market. The table below sets out what is actually known about each compound.

Compound	Primary target	Typical route	U.S. regulatory status
Elamipretide	Cardiolipin on the inner mitochondrial membrane	Subcutaneous, IV, topical	Prescription drug candidate
BPC-157	Growth factor signaling and tissue repair (mostly animal data)	Subcutaneous or oral	Not approved for human use
TB-500	Actin regulation and cell migration	Subcutaneous	Not approved for human use
IGF-1 LR3	IGF-1 receptor	Subcutaneous	Not approved for human use
GHK-Cu	Copper-binding and skin remodeling	Topical	Cosmetic use only

The comparison favors elamipretide in one specific way: it has published human trials and a structured regulatory path, while most peptides sold online have neither.

Safety, Sourcing, and Realistic Expectations

The same caution applies to questions such as where to buy bpc-157 peptide, because unregulated vials can vary widely in purity and identity. Compounds like long r3 insulin-like growth factor-1 raise similar concerns, and readers asking how does igf 1 lr3 work or is igf 1 lr3 safe should know that human safety data are limited.

Even inside mitochondria research, related molecules get misrepresented. Some people ask about l_car, a shorthand for L-carnitine, and assume it behaves like elamipretide; L-carnitine supports fatty-acid transport, but it does not bind cardiolipin.

If you have a diagnosed mitochondrial disorder, the practical path is a clinical trial, an expanded access program, or a specialist who tracks the FDA's current position. Self-treatment with research-grade peptides carries real risk and no guaranteed benefit.

COMMON QUESTIONS

Frequently Asked Questions

Is elamipretide FDA approved?

Elamipretide has been developed as a prescription drug candidate under the brand name Forzinity and has gone through FDA review for Barth syndrome, but its regulatory status has changed over time. It is not approved as a dietary supplement, cosmetic ingredient, or general wellness product. Check the FDA's current records for the latest decision.

What is elamipretide used for?

Elamipretide is studied mainly for Barth syndrome, primary mitochondrial myopathy, heart failure and reperfusion injury after a heart attack, and certain eye diseases such as dry age-related macular degeneration. All of these uses remain investigational, and none is approved as a general consumer use. It is not a treatment for aging, weight loss, or athletic performance.

Can I buy elamipretide online?

Elamipretide is not sold legally as an over-the-counter or research-chemist product for human use in the United States. Products labeled as elamipretide on gray-market sites are unverified and may contain the wrong compound or the wrong dose. Access normally comes through a clinical trial, an expanded access program, or a physician, and anyone with a mitochondrial diagnosis should consult a specialist.